Product news from 05/05/06 News Brief

Share this article:
Cephalon received FDA approval for Nuvigil (armodafinil) tablets for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome and shift-work sleep disorder. FDA approval of Nuvigil is contingent upon finalizing the product label. The FDA approved two new higher-dose formulations of Novartis’ high-blood pressure medication Diovan HCT (valsartan/hydrochlorothiazide)—320/12.5 mg and 320/25 mg. The new formulations will be commercially available by early June 2006. MGI Pharma and SuperGen received FDA approval for Dacogen (decitabine) for injection treatment of patients with myelodysplastic syndromes (MDS). Dacogen is expected to be commercially available during the second quarter of 2006.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.